Life Sciences Archives - Page 6 of 17 - EverGlade

Life Sciences

BARDA-BAA-advanced-medical-countermeasures

BARDA’s Modernized BAA: A New On-Ramp for Advanced Medical Countermeasure Development

Leave a Comment / All Posts, BARDA, Life Sciences / By

BARDA_FY23 Modernized BAA Solicitation – Amendment 7 The Biomedical Advanced Research and Development Authority (BARDA) has released its modernized Broad Agency Announcement (BAA-23-100-SOL-00004, Amendment 7), creating a flexible, multi-year pathway for industry to partner with the U.S. Government on advanced medical countermeasures (MCMs) for CBRN, pandemic influenza, and emerging infectious disease threats to the U.S.

BARDA’s Modernized BAA: A New On-Ramp for Advanced Medical Countermeasure Development Read More »

BARDA RFI Neuromuscular Junction

BARDA’s RRPV RFI on NMJ Micro-Physiological Systems for BoNT Evaluation

Leave a Comment / All Posts, BARDA, Life Sciences / By

RRPV_RFI_BoNT-NMJ RFI Final Post Overview of Solicitation The Rapid Response Partnership Vehicle (RRPV), on behalf of the Biomedical Advanced Research and Development Authority (BARDA), has released a Request for Information (RFI) focused on neuromuscular junction (NMJ) micro-physiological systems (MPS) for botulinum neurotoxin (BoNT) applications. Managed by Advanced Technology International (ATI), this RFI seeks to assess

BARDA’s RRPV RFI on NMJ Micro-Physiological Systems for BoNT Evaluation Read More »

BARDA RRPV RAPID Solicitation Rapid Antibody Production

BARDA’s RRPV 26-10-RAPID Solicitation for Rapid Antibody Production

Leave a Comment / All Posts, BARDA, Life Sciences / By

RRPV-26-10-RAPID The Biomedical Advanced Research and Development Authority (BARDA), through the Rapid Response Partnership Vehicle (RRPV), has released a new Request for Project Proposals (RPP) to stand up U.S.-based rapid antibody and protein binder production platforms that can go from pathogen gene sequence to immunoassay-ready reagents within weeks instead of months. This is a targeted opportunity to position platform

BARDA’s RRPV 26-10-RAPID Solicitation for Rapid Antibody Production Read More »

BARDA RFI ARDS Prevention

BARDA RFI on Host-Directed Therapeutics for ARDS Prevention

Leave a Comment / BARDA, Life Sciences / By

Overview of Solicitation The Biomedical Advanced Research and Development Authority (BARDA), within the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, has released a Request for Information (RFI)/Sources Sought Notice (SSN) titled “Host Directed Therapeutics for the Prevention of Progression to ARDS.” This effort, in support of BARDA’s

BARDA RFI on Host-Directed Therapeutics for ARDS Prevention Read More »

ARPA-H STOMP Program

ARPA-H STOMP Program: Advancing the Science of Microplastics and Human Health

Leave a Comment / All Posts, ARPA-H, Life Sciences / By

STOMP_ISO_ARPA-H-SOL-26-152 The Advanced Research Projects Agency for Health (ARPA-H) has released an Innovative Solutions Opening (ISO) for the Systematic Targeting of Microplastics (STOMP) program, signaling a major federal investment in understanding and addressing the health impacts of micro- and nano-plastics (MNPs). As mounting evidence links MNP exposure to a range of adverse health outcomes, ARPA-H

ARPA-H STOMP Program: Advancing the Science of Microplastics and Human Health Read More »

MCDC Host-Directed Therapeutics Initiative

MCDC’s Host-Directed Therapeutics Initiative

Leave a Comment / All Posts, CPE CBRND, Defense, Life Sciences / By

The Medical Chemical, Biological, Radiological, and Nuclear Defense Consortium (MCDC), managed by Advanced Technology International (ATI), has issued a Request for Information (RFI) focused on “Host-Directed Medical Countermeasures.” This effort, led in support of the Capability Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (CPE CBRND), represents an early step toward shaping a

MCDC’s Host-Directed Therapeutics Initiative Read More »

ARPA-H 1-CURE Initiative

ARPA-H’s 1-CURE Initiative to Revolutionize Universal Cancer Radiotherapy

Leave a Comment / All Posts, ARPA-H, Life Sciences / By

1-CURE_ISO_ARPA-H-SOL-26-147 Cancer remains one of the leading causes of death globally, with existing treatment modalities often limited by cost, accessibility, and effectiveness, particularly for metastatic disease. In response, the Advanced Research Projects Agency for Health (ARPA-H) has released an Innovative Solutions Opening (ISO) under solicitation ARPA-H-SOL-26-147 for the One Comprehensive Universal Radiotherapy for Everyone (1-CURE)

ARPA-H’s 1-CURE Initiative to Revolutionize Universal Cancer Radiotherapy Read More »

ARPA-H Delphi Program Draft Featured Image

ARPA-H’s Delphi Program Draft ISO Signals New Opportunities in Continuous Biosensing

Leave a Comment / All Posts, ARPA-H, Life Sciences / By

ARPA-H-SOL-26-153+DRAFT+Delphi+ISO Overview of the DELPHI Program The Advanced Research Projects Agency for Health (ARPA-H) has released a Draft Innovative Solutions Opening (ISO) for the Delphi program through its Resilient Systems Office (RSO). The draft announcement, ARPA-H-SOL-26-153, is intended to inform the research community about an upcoming funding opportunity and allow potential performers time to prepare

ARPA-H’s Delphi Program Draft ISO Signals New Opportunities in Continuous Biosensing Read More »

ARPA-H ADVOCATE Program

ARPA-H’s ADVOCATE Program: What Amendment 02 Means for Proposers

Leave a Comment / All Posts, ARPA-H, Life Sciences / By

ADVOCATEISO_ARPA-H-SOL-26-142_Amendment02 The Advanced Research Projects Agency for Health (ARPA-H) released Amendment 02 to its ADVOCATE solicitation (ARPA-H-SOL-26-142), refining technical expectations, evaluation criteria, and program execution details for one of its most ambitious artificial intelligence initiatives in healthcare. ADVOCATE is designed to accelerate the development, evaluation, and scalable deployment of clinical artificial intelligence (AI) agents that

ARPA-H’s ADVOCATE Program: What Amendment 02 Means for Proposers Read More »

ARPA-H CIRCLE Program

ARPA-H’s CIRCLE Program

Leave a Comment / All Posts, ARPA-H, Life Sciences / By

ISO+Amd+1+-+CIRCLE The Advanced Research Projects Agency for Health (ARPA-H), through its Resilient Systems Office (RSO), has released an Innovative Solutions Opening (ISO) titled Critical Illness Immunological Reprogramming and Control Point Learning Engine (CIRCLE), ARPA-H-SOL-26-139 . This solicitation reflects ARPA-H’s mandate to pursue bold, high-impact biomedical innovations that can transform patient outcomes at scale. With CIRCLE,

ARPA-H’s CIRCLE Program Read More »

BARDA domestic manufacturing essential medicines

BARDA Advances Domestic Manufacturing Capacity for Essential Medicines

Leave a Comment / BARDA, Life Sciences / By

BARDA 26-2-AM-LVP-RPP-Amendment 1 The Biomedical Advanced Research and Development Authority (BARDA), within the U.S. Department of Health and Human Services (HHS), has released a new Request for Project Proposals (RPP) aimed at strengthening the nation’s domestic pharmaceutical manufacturing base. Issued through the Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP Consortium), RPP 26-2-AM-LVP focuses on the commercial scale

BARDA Advances Domestic Manufacturing Capacity for Essential Medicines Read More »

DTRAs Six Basic Research Topics

Deep Dive Into DTRA’s Six Basic Research Topics

Leave a Comment / DTRA, Life Sciences / By

HDTRA125S0001 Topics Release Final Amendment 4 The Defense Threat Reduction Agency (DTRA), through its Research and Development (RD) Directorate and Chemical and Biological Technologies Department, has released Amendment 4 to its Broad Agency Announcement (BAA) titled Fundamental Research to Counter Weapons of Mass Destruction (C-WMD). This long-term funding vehicle reflects DTRA’s sustained commitment to advancing

Deep Dive Into DTRA’s Six Basic Research Topics Read More »

Scroll to Top